Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis.

Pourbaix A, Guérin F, Burdet C, Massias L, Chau F, Cattoir V, Fantin B.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00903-19. doi: 10.1128/AAC.00903-19. Print 2019 Aug.

PMID:
31160291
2.

Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Burdet C, Grall N, Linard M, Bridier-Nahmias A, Benhayoun M, Bourabha K, Magnan M, Clermont O, d'Humières C, Tenaillon O, Denamur E, Massias L, Tubiana S, Alavoine L, Andremont A, Mentré F, Duval X; CEREMI Group.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02244-18. doi: 10.1128/AAC.02244-18. Print 2019 Jun.

PMID:
30936104
3.

Oropharyngeal Bacterial Colonization after Chlorhexidine Mouthwash in Mechanically Ventilated Critically Ill Patients.

La Combe B, Mahérault AC, Messika J, Billard-Pomares T, Branger C, Landraud L, Dreyfuss D, Dib F, Massias L, Ricard JD.

Anesthesiology. 2018 Dec;129(6):1140-1148. doi: 10.1097/ALN.0000000000002451.

PMID:
30247201
4.

Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.

Burdet C, Loubet P, Le Moing V, Vindrios W, Esposito-Farèse M, Linard M, Ferry T, Massias L, Tattevin P, Wolff M, Vandenesch F, Grall N, Quintin C, Mentré F, Duval X, Lescure FX; CloCeBa study group.

BMJ Open. 2018 Sep 1;8(8):e023151. doi: 10.1136/bmjopen-2018-023151.

5.

Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli.

Berleur M, Guérin F, Massias L, Chau F, Poujade J, Cattoir V, Fantin B, de Lastours V.

J Antimicrob Chemother. 2018 Nov 1;73(11):3074-3080. doi: 10.1093/jac/dky283.

PMID:
30085154
6.

High-dose daptomycin in patients with infective endocarditis or sternal wound infections.

Peiffer-Smadja N, Abbara S, Rizk N, Pogliaghi M, Rondinaud E, Tesmoingt C, Massias L, Lucet JC, Alkhoder S, Armand-Lefèvre L, Lescure FX.

Clin Microbiol Infect. 2018 Oct;24(10):1106-1108. doi: 10.1016/j.cmi.2018.05.015. Epub 2018 Jun 4. No abstract available.

PMID:
29879481
7.

Pneumocystis Cytochrome b Mutants Associated With Atovaquone Prophylaxis Failure as the Cause of Pneumocystis Infection Outbreak Among Heart Transplant Recipients.

Argy N, Le Gal S, Coppée R, Song Z, Vindrios W, Massias L, Kao WC, Hunte C, Yazdanpanah Y, Lucet JC, Houzé S, Clain J, Nevez G.

Clin Infect Dis. 2018 Aug 31;67(6):913-919. doi: 10.1093/cid/ciy154. Erratum in: Clin Infect Dis. 2019 Jan 1;68(1):175.

PMID:
29514207
8.

In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.

Reissier S, Saleh-Mghir A, Guerin F, Massias L, Ghout I, Sinel C, Cattoir V, Cremieux AC.

J Antimicrob Chemother. 2018 Apr 1;73(4):981-986. doi: 10.1093/jac/dkx499.

PMID:
29329389
9.

Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.

Le Meur L, Tantet C, Lê MP, Desselas E, Bonnal C, Lillo-Le-Louet A, Sonneville R, Massias L, Giraud J, Descamps D, Yazdanpanah Y, Lariven S, Peytavin G.

J Antimicrob Chemother. 2018 Apr 1;73(4):1108-1110. doi: 10.1093/jac/dkx495. No abstract available.

PMID:
29294026
10.

Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii.

Robin C, Lê MP, Melica G, Massias L, Redjoul R, Khoudour N, Leclerc M, Beckerich F, Maury S, Hulin A, Cordonnier C.

J Antimicrob Chemother. 2017 Sep 1;72(9):2602-2606. doi: 10.1093/jac/dkx198.

PMID:
28651341
11.

Fatal invasive aspergillosis caused by Aspergillus niger after bilateral lung transplantation.

Atchade E, Jean-Baptiste S, Houzé S, Chabut C, Massias L, Castier Y, Brugière O, Mal H, Montravers P.

Med Mycol Case Rep. 2017 May 18;17:4-7. doi: 10.1016/j.mmcr.2017.05.002. eCollection 2017 Sep.

12.

Outbreak of Pneumocystis jirovecii Infection Among Heart Transplant Recipients: Molecular Investigation and Management of an Interhuman Transmission.

Vindrios W, Argy N, Le Gal S, Lescure FX, Massias L, Le MP, Wolff M, Yazdanpanah Y, Nevez G, Houze S, Dorent R, Lucet JC.

Clin Infect Dis. 2017 Oct 1;65(7):1120-1126. doi: 10.1093/cid/cix495.

PMID:
28549105
13.

Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.

Dupont H, Massias L, Jung B, Ammenouche N, Montravers P.

J Antimicrob Chemother. 2017 May 1;72(5):1429-1432. doi: 10.1093/jac/dkw568.

PMID:
28088767
14.

Staphylococcus aureus osteo-articular infection: usefulness of the determination of daptomycin serum concentration to explain a treatment failure.

Barreau S, Benaboud S, Kernéis S, Moachon L, Blanche P, Groh M, Massias L, Treluyer JM, Poyart C, Raymond J.

Int J Clin Pharmacol Ther. 2016 Nov;54(11):923-927.

PMID:
27509826
15.

Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli.

Alexandre K, Chau F, Guérin F, Massias L, Lefort A, Cattoir V, Fantin B.

J Antimicrob Chemother. 2016 Jul;71(7):1899-904. doi: 10.1093/jac/dkw066. Epub 2016 Mar 29.

PMID:
27029848
16.

Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.

Rossi B, Soubirou JF, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):424-30. doi: 10.1128/AAC.02018-15. Print 2016 Jan.

17.

Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.

Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, Da Silva D, Lasocki S, Laouénan C, Mentec H, Mentré F, Wolff M.

J Antimicrob Chemother. 2015 May;70(5):1487-94. doi: 10.1093/jac/dku569. Epub 2015 Jan 27.

PMID:
25630642
18.

Alveolar and serum concentrations of imipenem in two lung transplant recipients supported with extracorporeal membrane oxygenation.

Welsch C, Augustin P, Allyn J, Massias L, Montravers P, Allou N.

Transpl Infect Dis. 2015 Feb;17(1):103-5. doi: 10.1111/tid.12327. Epub 2015 Jan 9.

PMID:
25572932
19.

Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.

Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B.

J Antimicrob Chemother. 2015 May;70(5):1466-72. doi: 10.1093/jac/dku542. Epub 2015 Jan 5.

PMID:
25564564
20.

Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.

Lecefel C, Eloy P, Chauvin B, Wyplosz B, Amilien V, Massias L, Taburet AM, Francois H, Furlan V.

J Clin Pharm Ther. 2015 Feb;40(1):119-20. doi: 10.1111/jcpt.12234. Epub 2014 Nov 24.

PMID:
25417855
21.

Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.

Burdet C, Pajot O, Couffignal C, Armand-Lefèvre L, Foucrier A, Laouénan C, Wolff M, Massias L, Mentré F.

Eur J Clin Pharmacol. 2015 Jan;71(1):75-83. doi: 10.1007/s00228-014-1766-y. Epub 2014 Oct 21.

22.

Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

Couffignal C, Pajot O, Laouénan C, Burdet C, Foucrier A, Wolff M, Armand-Lefevre L, Mentré F, Massias L.

Br J Clin Pharmacol. 2014 Nov;78(5):1022-34. doi: 10.1111/bcp.12435.

23.

Very-high-dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid.

Réminiac F, Sonneville R, Massias L, Chochillon C, Wolff M.

Antimicrob Agents Chemother. 2014 Jun;58(6):3568-9. doi: 10.1128/AAC.02719-14. Epub 2014 Apr 14. No abstract available.

24.

Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.

de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R.

Intensive Care Med. 2014 Jul;40(7):998-1005. doi: 10.1007/s00134-014-3276-x. Epub 2014 Apr 1.

PMID:
24687298
25.

The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.

Bourgeois-Nicolaos N, Nguyen TT, Defrance G, Massias L, Alavoine L, Lefort A, Noel V, Senneville E, Doucet-Populaire F, Mentré F, Andremont A, Duval X.

Antimicrob Agents Chemother. 2014 May;58(5):2681-7. doi: 10.1128/AAC.02251-13. Epub 2014 Feb 24.

26.

Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.

Guillard T, Cambau E, Chau F, Massias L, de Champs C, Fantin B.

Antimicrob Agents Chemother. 2013 Dec;57(12):5830-5. doi: 10.1128/AAC.01489-13. Epub 2013 Sep 9.

27.

Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.

Grall N, Massias L, Nguyen TT, Sayah-Jeanne S, Ducrot N, Chachaty E, de Gunzburg J, Andremont A.

Antimicrob Agents Chemother. 2013 Nov;57(11):5423-5. doi: 10.1128/AAC.00039-13. Epub 2013 Aug 19.

28.

Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.

Tattevin P, Saleh-Mghir A, Davido B, Ghout I, Massias L, Garcia de la Maria C, Miró JM, Perronne C, Laurent F, Crémieux AC.

Antimicrob Agents Chemother. 2013 Mar;57(3):1157-62. doi: 10.1128/AAC.01669-12. Epub 2012 Dec 17.

29.

Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Saleh-Mghir A, Dumitrescu O, Dinh A, Boutrad Y, Massias L, Martin E, Vandenesch F, Etienne J, Lina G, Crémieux AC.

Antimicrob Agents Chemother. 2012 Dec;56(12):6291-7. doi: 10.1128/AAC.00926-12. Epub 2012 Oct 1.

30.

Breakthrough invasive mould infections in patients treated with caspofungin.

Pang KA, Godet C, Fekkar A, Scholler J, Nivoix Y, Letscher-Bru V, Massias L, Kauffmann-Lacroix C, Elsendoorn A, Uzunov M, Datry A, Herbrecht R.

J Infect. 2012 Apr;64(4):424-9. doi: 10.1016/j.jinf.2011.12.015. Epub 2011 Dec 29.

PMID:
22227384
31.

Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.

Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B.

Antimicrob Agents Chemother. 2012 Mar;56(3):1376-81. doi: 10.1128/AAC.06233-11. Epub 2012 Jan 3.

32.

Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.

Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Crémieux AC.

Antimicrob Agents Chemother. 2011 Oct;55(10):4589-93. doi: 10.1128/AAC.00675-11. Epub 2011 Aug 8.

33.

Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients.

Bazin C, Guinedor A, Barau C, Gozalo C, Grimbert P, Duvoux C, Furlan V, Massias L, Hulin A.

J Pharm Biomed Anal. 2010 Dec 1;53(4):997-1002. doi: 10.1016/j.jpba.2010.06.022. Epub 2010 Jun 26.

PMID:
20674215
34.

Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.

Allou N, Cambau E, Massias L, Chau F, Fantin B.

Antimicrob Agents Chemother. 2009 Oct;53(10):4292-7. doi: 10.1128/AAC.01664-08. Epub 2009 Jul 27.

35.

Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.

Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A, Mentré F.

J Infect Dis. 2009 Aug 1;200(3):390-8. doi: 10.1086/600122.

36.

[Painful peripheral neuropathy associated with voriconazole during the treatment of chronic cavitary pulmonary aspergillosis].

Gendrot A, de La Blanchardière A, de La Gastine B, Fromager G, Massias L, Verdon R.

Rev Med Interne. 2010 Feb;31(2):163-6. doi: 10.1016/j.revmed.2009.02.021. Epub 2009 May 19. French.

PMID:
19457596
37.

Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.

Muller-Serieys C, Saleh Mghir A, Massias L, Fantin B.

Antimicrob Agents Chemother. 2009 May;53(5):2145-8. doi: 10.1128/AAC.01163-08. Epub 2009 Mar 9.

38.

Interest of BIS monitoring to guide propofol infusion during the anhepatic phase of orthotopic liver transplantation.

Tremelot L, Restoux A, Paugam-Burtz C, Dahmani S, Massias L, Peuch C, Belghiti J, Mantz J.

Ann Fr Anesth Reanim. 2008 Dec;27(12):975-8. doi: 10.1016/j.annfar.2008.10.005. Epub 2008 Nov 22.

PMID:
19028068
39.

Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation.

Ruiz S, Papy E, Da Silva D, Nataf P, Massias L, Wolff M, Bouadma L.

Intensive Care Med. 2009 Jan;35(1):183-4. doi: 10.1007/s00134-008-1269-3. Epub 2008 Sep 16. No abstract available.

PMID:
18795256
40.

Plasmodium falciparum malaria and atovaquone-proguanil treatment failure.

Durand R, Prendki V, Cailhol J, Hubert V, Ralaimazava P, Massias L, Bouchaud O, Le Bras J.

Emerg Infect Dis. 2008 Feb;14(2):320-2. doi: 10.3201/eid1402.070945.

41.

The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient.

Quintard H, Papy E, Massias L, Lasocki S, Arnaud P, Desmonts JM, Montravers P.

Ther Drug Monit. 2008 Feb;30(1):117-9. doi: 10.1097/FTD.0b013e31815c1672.

PMID:
18223474
42.

Amiodarone-induced hyperthyroidism during massive weight loss following gastric bypass.

Bourron O, Ciangura C, Bouillot JL, Massias L, Poitou C, Oppert JM.

Obes Surg. 2007 Nov;17(11):1525-8.

PMID:
18219784
43.

Effects of biliary obstruction on the penetration of ciprofloxacin and cefotaxime.

Dhalluin-Venier V, Bazin C, Massias L, Farah RB, Boytchev I, Fritsch J, Choury AD, Prat F, Buffet C, Furlan V, Pelletier G.

Eur J Gastroenterol Hepatol. 2008 Feb;20(2):127-30. doi: 10.1097/MEG.0b013e3282f1c985.

PMID:
18188033
44.

Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo.

Bourgeois-Nicolaos N, Massias L, Couson B, Butel MJ, Andremont A, Doucet-Populaire F.

J Infect Dis. 2007 May 15;195(10):1480-8. Epub 2007 Apr 3.

PMID:
17436228
45.

Cortical consequences of in vivo blockade of monocarboxylate transport during brain development in mice.

Adle-Biassette H, Olivier P, Verney C, Fontaine RH, Evrard P, Hénin D, Massias L, Gressens P, Baud O.

Pediatr Res. 2007 Jan;61(1):54-60.

PMID:
17211141
46.

Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis.

Aslangul E, Massias L, Meulemans A, Chau F, Andremont A, Courvalin P, Fantin B, Ruimy R.

Antimicrob Agents Chemother. 2006 Nov;50(11):3615-21.

47.

Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations.

Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J.

Microbes Infect. 2006 Sep;8(11):2599-604. Epub 2006 Aug 10.

PMID:
16962361
48.

Teicoplanin-containing cement spacers for treatment of experimental Staphylococcus aureus joint prosthesis infection.

Ismael F, Bléton R, Saleh-Mghir A, Dautrey S, Massias L, Crémieux AC.

Antimicrob Agents Chemother. 2003 Oct;47(10):3365-7.

49.

Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.

Camus M, Henneré G, Baron G, Peytavin G, Massias L, Mentré F, Farinotti R.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):583-7. Epub 2003 Sep 19.

PMID:
14504851
50.

Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Pavie J, Lefort A, Ploy MC, Massias L, Chau F, Garry L, Denis F, Fantin B.

Antimicrob Agents Chemother. 2003 Jun;47(6):2018-21.

Supplemental Content

Loading ...
Support Center